Oramed Pharmaceuticals, Inc.
Period Ending Aug 31, 2013 Aug 31, 2012 Aug 31, 2011 Aug 31, 2010
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 2,272 1,681 1,159 1,464
Sales, General and Admin. 2,032 1,203 1,276 1,509
Non-Recurring Items - - - -
Other - - - -
Operating Income (4,304) (2,884) (2,435) (2,973)
Income From Continuing Operations
Add'l Income/Expense Items 180 (171) 869 10
Earnings Before Interest and Tax (4,123) (3,055) (1,566) (2,962)
Interest Expense 313 199 19 -
Earnings Before Tax (4,437) (3,254) (1,585) (2,962)
Income Tax (205) 90 (24) 15
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (4,232) (3,344) (1,561) (2,977)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (4,232) (3,344) (1,561) (2,977)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (4,232) (3,344) (1,561) (2,977)